We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

46 hedge funds and large institutions have $27.9M invested in Lumos Pharma, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 19 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less capital invested

Capital invested by funds: $30.5M → $27.9M (-$2.61M)

28% less funds holding

Funds holding: 6446 (-18)

53% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 19

54% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 28

72% less call options, than puts

Call options by funds: $467K | Put options by funds: $1.67M

Holders
46
Holders Change
-18
Holders Change %
-28.13%
% of All Funds
1.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
9
Reduced
19
Closed
28
Calls
$467K
Puts
$1.67M
Net Calls
-$1.2M
Net Calls Change
-$365K

LUMO Hedge Fund Activity: Q1 2020 in Review

46 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2020, worth a combined $27.9M — down 8.6% from $30.5M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of LUMO and 13 opened new positions — a net loss of 15 holders — while 19 trimmed existing stakes and 9 added.

The largest buyer was Deerfield Management, opening a new position worth an estimated $13.1M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.3M sold.

  • 46 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2020, down from 64 in Q4 2019.
  • Funds reported $27.9M of Lumos Pharma, Inc. Common Stock stock for Q1 2020, down 8.6% quarter-over-quarter.
  • 13 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2020 and 28 closed out, a net change of -15 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2020 was Deerfield Management, an estimated $13.1M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q1 2020 was Acadian Asset Management, an estimated $1.3M sold.

Based on aggregated 13F filings for Q1 2020.